<DOC>
	<DOCNO>NCT00281853</DOCNO>
	<brief_summary>RATIONALE : Learning effect chemotherapy biological therapy nerve function may help doctor plan treatment help patient live comfortably . PURPOSE : This clinical trial study peripheral neuropathy patient receive chemotherapy biological therapy cancer .</brief_summary>
	<brief_title>Nerve Changes Patients Who Are Undergoing Chemotherapy Biological Therapy Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine change peripheral nerve function cancer patient treatment chemotherapy biologic therapy . - Determine clinical measurement hearing-related air bone conduction vibratory sensation patient . - Correlate change orthostatic blood pressure use Vasotrac automate blood pressure device standard clinical automate blood pressure equipment . - Determine patient 's perception hearing quality treatment chemotherapy biologic therapy . OUTLINE : This multicenter study . Patients undergo 1-hour peripheral nerve function assessment , include hearing , vibratory sensation , blood pressure test , baseline 4 , 8 , 12 week treatment chemotherapy biologic therapy . PROJECTED ACCRUAL : A total 20 patient accrue study .</detailed_description>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis cancer Scheduled treat 1 follow agent : Cisplatin/paclitaxel combination Biologic therapy highdose interferon alfa PATIENT CHARACTERISTICS : Normal vision OR vision correct glass contact lenses No disease disorder reduce peripheral nerve function , include follow : Diabetes mellitus HIV/AIDS Uremia Spinal injury Alcoholism CNS problem No hearing impairment PRIOR CONCURRENT THERAPY : No prior biologic therapy neurotoxic chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>neurotoxicity</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>